Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART

Antivir Ther. 2004 Apr;9(2):291-6.

Abstract

We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load < or = 500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active*
  • Cohort Studies
  • Drug Therapy, Combination
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Protease Inhibitors / blood*
  • Humans
  • Italy
  • Patient Compliance*
  • Predictive Value of Tests
  • RNA, Viral / blood
  • Reverse Transcriptase Inhibitors / blood*
  • Surveys and Questionnaires
  • Viral Load*

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral
  • Reverse Transcriptase Inhibitors